THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED AMENDMENT TO AGREEMENTAgreement • December 2nd, 2019 • Kitov Pharma Ltd. • Pharmaceutical preparations
This Amendment Number 2 (the “Amendment”) to that certain Agreement previously entered into as of December 27, 2018, by and between Kitov Pharma Ltd., a company existing under the laws of the State of Israel with a principal place of business at One Azrieli Center, Round Tower, Floor 19, Tel Aviv, Israel (“Kitov”), and Coeptis Pharmaceuticals, Inc., a Pennsylvania corporation with a principal place of business at 105 Bradford Road, Suite 420, Wexford, PA 15090 (“Coeptis”), as amended, (“the Agreement”). Kitov and Coeptis are sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
